• English
    • Ελληνικά
  • English 
    • English
    • Ελληνικά
  • Login
Browsing by Subject 
  •   Home
  • Browsing by Subject
  •   Home
  • Browsing by Subject
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browsing by Subject "Skin toxicity"

  • 0-9
  • Α
  • Β
  • Γ
  • Δ
  • Ε
  • Ζ
  • Η
  • Θ
  • Ι
  • Κ
  • Λ
  • Μ
  • Ν
  • Ξ
  • Ο
  • Π
  • Ρ
  • Σ
  • Τ
  • Υ
  • Φ
  • Χ
  • Ψ
  • Ω
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sort by:

Order:

Results:

Now showing items 1-11 of 11

  • title
  • submit date
  • accessioned date
  • ascending
  • descending
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
    • Article  

      Docetaxel (Taxotere™) is active in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG) 

      Cerny, T.; Kaplan, S.; Pavlidis, Nicholas; Schöffski, P.; Epelbaum, R.; Meerbeek, J. van; Wanders, J.; Franklin, H. R.; Kaye, Stanley B. (1994)
      In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced non-small-cell lung cancer (NSCLC) with the new semisynthetic taxoid docetaxel (Taxotere). Six patients were ineligible; of ...

    • Article  

      Docetaxel (Taxotere™), a novel taxoid, in the treatment of advanced colorectal carcinoma: An EORTC Early Clinical Trials Group Study 

      Sternberg, Cora N.; Huinink, W. W. Ten Bokkel; Smyth, J. F.; Bruntsch, V.; Dirix, L. Y.; Pavlidis, Nicholas; Franklin, H. R.; Wanders, S.; Bail, N. Le; Kaye, Stanley B. (1994)
      Docetaxel (Taxotere), a new semisynthetic taxoid, is a potentially important chemotherapeutic agent for the treatment of cancer. Forty patients with bidimensionally measurable advanced adenocarcinoma of the colon were ...

    • Article  

      Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety 

      Lazaridis, G.; Pentheroudakis, George; Pavlidis, Nicholas (2008)
      Neoadjuvant chemotherapy is used in non-metastatic breast cancer in order to eradicate micrometastatic deposits early during disease course, as well as in order to decrease tumour bulk and render surgery feasible or ...

    • Article  

      Mitoxantrone: An active new agent in the treatment of advanced breast cancer 

      Stuart-Harris, R. C.; Bozek, T.; Pavlidis, Nicholas; Smith, I. E. (1984)
      Sixty-five patients with advanced breast carcinoma were treated with mitoxantrone, an anthracenedione with structural similarities to adriamycin. The series included 26 patients who had received no prior chemotherapy. ...

    • Article  

      Multicentre phase II pharmacological evaluation of rhizoxin 

      McLeod, H. L.; Murray, L. S.; Wanders, J.; Setanoians, A.; Graham, M. A.; Pavlidis, Nicholas; Heinrich, B.; Huinink, W. W. Ten Bokkel; Wagener, D. J. Th; Aamdal, S.; Verweij, J. (1996)
      Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines and xenograft models. ...

    • Article  

      Oral chemotherapy in advanced breast cancer. A reconsideration 

      Pavlidis, Nicholas (1985)

    • Article  

      Phase II clinical trials with rhizoxin in breast cancer and melanoma 

      Hanauske, A. R.; Catimel, G.; Aamdal, S.; Huinink, W. W. Ten Bokkel; Paridaens, R.; Pavlidis, Nicholas; Kaye, Stanley B.; Velde, A. Te; Wanders, J.; Verweij, J. (1996)
      Rhizoxin is a new anti-tumour agent isolated from the pathogenic fungus Rhizopus chinensis. It has shown broad activity against murine tumour models and is also active against vinca alkaloid-resistant cells. The purpose ...

    • Article  

      Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG) 

      Chollet, P.; Schöffski, P.; Weigang-Köhler, K.; Schellens, J. H. M.; Cure, H.; Pavlidis, Nicholas; Grünwald, V.; Boer, R. De; Wanders, J.; Fumoleau, P. (2003)
      S-1 is a new oral fluorinated pyrimidine derivate, in which the oral 5-fluorouracil (5-FU) prodrug, tegafur, was combined with two 5-FU-modulating substances, 5-chloro-2,4-dihydroxypyridine (gimeracil), and potassium oxonate ...

    • Article  

      Single agent activity of rhizoxin in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group 

      Kaplan, S.; Hanauske, A. R.; Pavlidis, Nicholas; Bruntsch, U.; Velde, A. Te; Wanders, J.; Heinrich, B.; Verweij, J. (1996)
      In a multicentre trial of the EORTC-Early Clinical Trials Group (ECTG) we treated 31 chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC) with rhizoxin, a novel tubulin-binding agent. The drug was ...

    • Article  

      Weekday on-weekend off oral capecitabine: A phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy 

      Pentheroudakis, George; Pappas, P.; Golfinopoulos, Vassilis; Fountzilas, George; Nikolaidou, M.; Boumba, V. A.; Vougiouklakis, T.; Nikiforidis, L.; Tzamakou, E.; Siarabi, O.; Marselos, M.; Pavlidis, Nicholas (2007)
      Background: Although protracted intravenous 5-fluorouracil is superior to bolus regimens in terms of tumour exposure to the drug during DNA synthesis as well as activity and safety, the oral fluoropyrimidine capecitabine ...

    • Article  

      Weekly paclitaxel combined with pegylated liposomal doxorubicin (Caelyx ™) given every 4 weeks: Dose-finding and pharmacokinetic study in patients with advanced solid tumors 

      Briassoulis, E. Ch; Pentheroudakis, George; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Pavlidis, Nicholas (2004)
      Background: We aimed to define the maximum tolerated dose (MTD) and characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Caelyx™) and weekly paclitaxel (wPTX), and to investigate pharmacokinetics ...

      Browse

      EverywhereCommunities & CollectionsBy Submission DateAuthorsTitlesSubjectsBy TypeBy DepartmentBy Faculty

      My Account

      Login
      Πνευματικά δικαιώματα ©  Βιβλιοθήκη Πανεπιστημίου Κύπρου
      Contact Us | Send Feedback
      Οδηγίες κατάθεσης διδακτορικής διατριβής
      Open Access
      ORCiD